Inside AGA

AGA’s 2018 Presidential Plenary session was packed, and excitement in the room was palpable! On the stage sat Sheila Crowe, our outgoing president, with David Lieberman, our incoming president. Our new logo was proudly and prominently displayed. In addition to expert presentations on eosinophilic esophagitis, colon cancer and inflammatory bowel disease, several abstracts were highlighted. […]


The inaugural Crohn’s & Colitis Congress™ (Jan. 18-20, 2018, Las Vegas, Nevada) gathered more than 1,250 inflammatory bowel disease (IBD) health care professionals and featured more than 250 abstracts — with the goal of advancing research and transforming the care of IBD patients. The Crohn’s & Colitis Congress is a new partnership between the Crohn’s […]

Plan B
Quick Hits

 Medical treatment options for patients with inflammatory bowel diseases (IBD) — Crohn’s disease and ulcerative colitis (UC) — have rapidly expanded with several different classes of medications now available. Traditionally, conventional therapy has consisted of mesalamine, steroids and immunomodulators, but in the era of biologic therapy, new options are available. However, variability remains in approaches […]

Quick Hits

Physicians who care for patients with inflammatory bowel disease (IBD) must be aware of the unique health maintenance issues facing these patients in order to deliver appropriate medical care.1 Studies have shown that patients with IBD do not receive routine preventive care at the same rate as patients with other medical conditions.2 Recent data also […]

Quick Hits

In the realm of inflammatory bowel disease (IBD), endpoints can be based on many things. We commonly use subjective assessments and complement these with more objective evaluations, including laboratory, endoscopic and radiologic studies. A great deal depends on the context in which these are considered: are they in reference to an individual patient or to […]